Beverly Drucker, MD, PhD
Assistant Professor of Medicine (Medical Oncology)Cards
About
Research
Publications
2009
Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study
Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM. Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study. Clinical Genitourinary Cancer 2009, 7: e58-e65. PMID: 19815483, DOI: 10.3816/cgc.2009.n.025.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaMulticenter phase I/II studyPhase I/II studyStage IV renal cell carcinomaPF-3512676II studyCell carcinomaAntitumor activityAdvanced metastatic renal cell carcinomaToll-like receptor 9 agonistMetastatic renal cell carcinomaAdvanced renal cell carcinomaLocal injection site reactionsPhase IGrade 3 fatigueGrade 4 AEsModest antitumor activityObjective response rateDose-limiting toxicityFlu-like symptomsInjection site reactionsReceptor 9 agonistSingle-agent treatmentPhase II expansionOpen label
2005
Renal cell carcinoma: Current status and future prospects
Drucker BJ. Renal cell carcinoma: Current status and future prospects. Cancer Treatment Reviews 2005, 31: 536-545. PMID: 16236454, DOI: 10.1016/j.ctrv.2005.07.009.Peer-Reviewed Original ResearchConceptsAdvanced renal cell carcinomaRenal cell carcinomaTotal nephrectomyLocalized Renal Cell CarcinomaStandard systemic treatmentSubset of patientsMost patientsSystemic treatmentCurative treatmentRadical nephrectomyPoor prognosisCell carcinomaUnderlying pathophysiologyStandard treatmentRenal tumorsInvasive treatmentNew agentsTumor growthNephrectomyPatientsEarly detectionMolecular pathwaysSurgeryTreatmentDiagnostic methodsBladder cancer. Clinical practice guidelines in oncology.
Montie JE, Bahnson RR, Cohen SM, Drucker B, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Seigne J, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. Clinical practice guidelines in oncology. Journal Of The National Comprehensive Cancer Network 2005, 3: 4-5, 19-34. PMID: 19813320.Peer-Reviewed Original ResearchConceptsUrothelial tumorsCombined-modality approachIndividual patient's likelihoodClinical practice guidelinesStage of diseaseSpectrum of diseaseRange of prognosesCategories of diseaseUrothelial tractExtensive diseaseMetastatic diseaseStandard therapyMost recurrencesNew lesionsPatient's likelihoodOrgan preservationImproved outcomesMolecular stagingPractice guidelinesSurgical proceduresRadiation therapyGuide managementNew agentsAdvanced stageNew treatments
2004
Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma
Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ. Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma. Journal Of Clinical Oncology 2004, 22: 3720-3725. PMID: 15365068, DOI: 10.1200/jco.2004.10.155.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaRenal cell carcinomaGrade 3 sensory neuropathyPartial responseSensory neuropathyCell carcinomaM2 groupAdvanced renal cell carcinomaToxicity of bortezomibPhase II trialAssessable patientsStable diseaseII trialInterferon alfaUnacceptable toxicityClinical responseCytokine therapyCombination therapyIntravenous administrationNovel agentsIndividual patientsDose reductionResponse durationHigh doseAntitumor effects
2003
Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma
Drucker B, Bacik J, Ginsberg M, Marion S, Russo P, Mazumdar M, Motzer R. Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma. Investigational New Drugs 2003, 21: 341-345. PMID: 14578682, DOI: 10.1023/a:1025472712456.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaAdvanced renal cell carcinomaPhase II trialII trialCell carcinomaMemorial Sloan Kettering Cancer Center databaseMetastatic renal cell carcinomaCancer Center databaseProgression of diseaseMonths of startEvaluable patientsMedian TTPPartial responseCell patientsDisease progressionPatientsTreatment efficacyCenter databaseZD1839Antitumor activityProgressionTrialsMonthsFurther studiesCarcinomaPrognostic Factors for Metastatic Kidney Cancer
Drucker BJ, Mazumdar M, Motzer RJ. Prognostic Factors for Metastatic Kidney Cancer. Cancer Treatment And Research 2003, 116: 139-153. PMID: 14650830, DOI: 10.1007/978-1-4615-0451-1_8.Peer-Reviewed Original ResearchConceptsResponse rateMetastatic renal cell carcinomaStudy of immunotherapyEffective systemic therapyMetastatic kidney cancerStandard cytotoxic chemotherapyRenal cell cancerSpontaneous tumor regressionRenal cell carcinomaSignificant antitumor effectHormonal therapyUntreated patientsCytotoxic chemotherapyHormone therapyMetastatic RCCSystemic therapyPrognostic factorsCell cancerLymphocytic infiltrationPoor prognosisCell carcinomaRenal tumorsTumor regressionKidney cancerAntitumor effects
2002
Prognostic factors for biologic therapy in kidney cancer
Drucker BJ. Prognostic factors for biologic therapy in kidney cancer. Current Urology Reports 2002, 3: 31-36. PMID: 12084217, DOI: 10.1007/s11934-002-0008-5.Peer-Reviewed Original ResearchConceptsPrior nephrectomyCytokine therapyPrognostic factorsGood performance statusNormal lactate dehydrogenaseMajority of patientsLevels of cytokinesPresence of eosinophilsRenal cell cancerSubpopulations of lymphocytesLack of anemiaBiologic therapyPerformance statusImproved survivalCell cancerDisease characteristicsTumor responseNormal calciumImmune parametersInterleukin-2Kidney cancerTherapeutic benefitResponse rateTherapyLactate dehydrogenase
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsParallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033Recruiting ParticipantsA Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
HIC ID2000032270RoleSub InvestigatorPrimary Completion Date12/15/2027Recruiting ParticipantsRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsA Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
HIC ID2000031542RoleSub InvestigatorPrimary Completion Date01/31/2026Recruiting Participants
Clinical Care
Overview
Beverly Drucker, MD, PhD, specializes in medical oncology and hematology. She employs a range of cancer treatments, including chemotherapy and targeted therapies. Her approach emphasizes personalized care, ensuring that each treatment plan is suited to the specific requirements of her patients.
As an assistant professor of medicine (medical oncology) at Yale School of Medicine, Dr. Drucker is actively involved in several clinical trials exploring innovative treatments for various cancers, including lymphoma, prostate cancer, head and neck cancers, lung cancer, and pancreatic cancer. These trials aim to evaluate new therapeutic combinations and strategies to enhance treatment efficacy and improve patient care.
Dr. Drucker received her medical degree from Columbia University College of Physicians and Surgeons and completed her residency in internal medicine. She also holds a doctoral degree from Columbia University School of Graduate Arts and Sciences.
Fact Sheets
Hormonal Therapy for Cancer
Learn More on Yale MedicinePeritoneal Cancer
Learn More on Yale MedicineBreast Cancer
Learn More on Yale MedicineNeoplasm (Tumor)
Learn More on Yale Medicine
Yale Medicine News
News & Links
News
- May 01, 2023
Connecticut Magazine’s 2023 “Top Doctors” issue recognizes 81 Smilow Cancer Hospital and Yale Cancer Center physicians
- February 02, 2023
Smilow Breast Cancer Care Referrals in Greenwich and Stamford
- September 01, 2022Source: Health Extensions
Specialized Team Tackles Gynecologic Cancers
- May 03, 2022
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as Connecticut Magazine 'Best Doctors'
Get In Touch
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.